SCHEMBL21564652

SCHEMBL21564652

CC(C)(C)OC(=O)N1CCN(c2nc(Br)c[nH]c2=O)CC1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GBA1 P04062 2/20 0.47
KCNH2 Q12809 2/20 0.44
KIT P10721 2/20 0.43
CKS1B P61024 2/20 0.42
SKP1 P63208 2/20 0.42
SKP2 Q13309 2/20 0.42
MAPT P10636 2/20 0.42
ALDH1A1 P00352 1/20 0.42
LMNA P02545 1/20 0.42
TLR9 Q9NR96 1/20 0.41
OPRM1 P35372 1/20 0.41
OPRD1 P41143 1/20 0.41
OGFRL1 Q5TC84 1/20 0.41
MAP4K4 O95819 1/20 0.41
DDB1 Q16531 1/20 0.40
CRBN Q96SW2 1/20 0.40
GPR119 Q8TDV5 2/20 0.39
KDM4E B2RXH2 1/20 0.39
THRB P10828 1/20 0.39
BACE1 P56817 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23258216 0.86 GBA1 (0.45) GBA1KCNH2KITCKS1BSKP1
SCHEMBL21564523 0.81 GBA1 (0.41) GBA1KITCKS1BSKP1SKP2
SCHEMBL21552826 0.80 KMT2A (0.37) GBA1KITALDH1A1LMNA
SCHEMBL5234761 0.78 KIT (0.47) GBA1KITCKS1BSKP1SKP2
SCHEMBL21564641 0.77 HSD17B10 (0.44) GBA1KITCKS1BSKP1SKP2
SCHEMBL6287049 0.77 MAP4K4 (0.52) GBA1KCNH2KITCKS1BSKP1
SCHEMBL24485823 0.77 GBA1 (0.47) GBA1KCNH2KITCKS1BSKP1
SCHEMBL21564480 0.76 MAPT (0.39) GBA1KITCKS1BSKP1SKP2
SCHEMBL21552889 0.76 HRH4 (0.48)
SCHEMBL17310150 0.76 TLR9 (0.51) GBA1KITCKS1BSKP1SKP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112513020-B KDM1A inhibitors for the treatment of diseases 伊美格生物科学公司 2024-02-23 CN disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES INC (US) 2023-08-10 US disclosed
CN-112513020-A KDM1A inhibitors for the treatment of disease 伊美格生物科学公司 2021-03-16 CN disclosed
WO-2019217972-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2019-11-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230250090-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A GBA1 3344/4885KCNH2 2384/4885KIT 2064/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.